QpiAI Announces Dawn of Quantum Era in India With 25 Qubit Quantum Computer
QpiAI, a leader in quantum computing and generative AI, announced its First Quantum computer launch code named QpiAIIndusQuantum Computer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415961497/en/
QpiAI Gen-1 25 qubit Quantum computer Indus, picture from QpiAI Bangalore centre with CEO Dr Nagendra Nagaraja (Left) and VP of Quantum hardware Dr Manjunath R V (Right).
Dr Nagendra Nagaraja, CEO and Founder of QpiAI, said, "We are excited about our roadmap to commercialize quantum computers, leveraging large-scale qubit integration and logical qubits. The T1 and T2 times for our current 25-Qubit Indus Quantum Computer are 30 μs and 25 μs, respectively, characterized by our in-house developed quantum control electronics cluster, and are expected to increase to 100 μs soon. Furthermore, with our patented qubit architecture, we expect to reach a T1 time of 1 ms in early 2026. With single-qubit gate fidelity of 99.7% and two-qubit gate fidelity of 96%, supporting all native gate sets, our system is interfaced with QpiAI quantum software SDKs for application development. We will soon be expanding to 64-qubit quantum computers. We will have rich partnerships with fellow component suppliers, large pharma and chemical companies, data center players, and hyperscalers to commercialize quantum computing. Our key IP lies in using an AI-based agentic system to manufacture qubits and fine-tune them to obtain desired fidelity, error correction, and noise levels, where the Agentic AI system in our datacenter works in a closed loop with the quantum computer."
Department of Science and Technology (DST) who is also shareholder of QpiAI via NQM (National Quantum Mission) announced QpiAI Indus Quantum computer in a LinkedIn post
QpiAI Quantum and AI Full-Stack Vertical Integration
QpiAI has developed full-stack quantum computing technology vertically integrating AI and Quantum computing systems combining AI, quantum computers, algorithms, software, and applications. The Gen-1 QpiAI system is built with efficient Quantum-HPC integration with a colocated HPC datacenter for high-throughput and low-latency computing. The QpiAI quantum applications stack combines AI-driven quantum compilation with application-specific architectures for maximizing hybrid quantum-classical performance. QpiAI Quantum software platforms and products, including QpiAI-Logistics, QpiAI-Opt, QpiAI-ML, QpiAI-Pharma, and QpiAI-Matter, are targeted for core quantum applications in logistics, finance, material discovery, and pharma industries.
QpiAI Quantum QPU Technology
QpiAI quantum computers use superconducting qubits and roadmap to experiment with CMOS-based spin qubits in future models. The current generation of qubits is based on various architectures of superconducting qubits design. QpiAI NISQ (Noisy Intermediate-Scale Quantum) qubits and QpiAI FTQC (Fault-tolerant Quantum Computing) qubits are based on QpiAI proprietary qubit architecture named QpiAI Qubits. Transmon qubits are stabilized and error-corrected based on the surface codes with various distances. For higher reliability in fault-tolerant computing, QpiAI FTQC Qubits are error-corrected using Q-LDPC codes with new architectures invented by QpiAI to ensure high performance and low error rates.
Quantum computing today faces limited scalability and reliability challenges due to errors from decoherence, noise, and gate inaccuracies, impacting readiness for industrial applications. To address these, QpiAI is advancing error mitigation on NISQ devices with built-in Surface code schemes, and implementing Q-LDPC codes within our fault-tolerant roadmap. We aim to create scalable, reliable quantum systems capable of supporting complex, high-impact applications.
AI Technology
QpiAI has built advanced next generation generative AI and agentic AI systems that can autonomously navigate complex scenarios and build emergent intelligence through agent-based modeling. Our optimized data-to-intelligence stack and high-performance infrastructure enables modeling and automation at unprecedented scales, while ensuring a seamless transition to quantum-based modeling in the future with the optimal combination of bits, qubits, and neurons.
About QpiAI
QpiAI (https://www.qpiai.tech) is a Bangalore based deep-tech startup pioneering the convergence of Artificial Intelligence and Quantum Computing to solve some of the world’s most complex industrial and scientific challenges. QpiAI’s vertically integrated stack enables seamless innovation across hardware, software, and applications. The portfolio includes QpiAI-Explorer, an education platform; QpiAI-Quantum, offering SDKs, compilers, and simulators for quantum development; QpiAI-Opt, a powerful optimization engine for scientific and industrial use cases; QpiAI-Logistics, for route planning and supply chain optimization; QpiAI-Pharma, designed for drug discovery and protein-ligand modeling; QpiAI-Pro, a generative AI development suite; and QpiAI Agent-Hive, enabling intelligent agentic AI workflows.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415961497/en/
Contacts
Contact email: info@qpiai.tech
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom